Published in Nano Lett on October 22, 2008
Gold nanoparticles for biology and medicine. Angew Chem Int Ed Engl (2010) 4.14
Multimodality imaging probes: design and challenges. Chem Rev (2010) 2.61
Atherosclerotic plaque composition: analysis with multicolor CT and targeted gold nanoparticles. Radiology (2010) 2.43
Spectroscopic (multi-energy) CT distinguishes iodine and barium contrast material in MICE. Eur Radiol (2010) 1.84
Multimodality cardiovascular molecular imaging, Part II. Circ Cardiovasc Imaging (2009) 1.82
MRI of carotid atherosclerosis: clinical implications and future directions. Nat Rev Cardiol (2010) 1.78
Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov (2011) 1.78
Nanoparticles for biomedical imaging: fundamentals of clinical translation. Mol Imaging (2010) 1.75
Nanotechnology in medical imaging: probe design and applications. Arterioscler Thromb Vasc Biol (2008) 1.55
X-ray-computed tomography contrast agents. Chem Rev (2012) 1.52
Multimodality imaging: beyond PET/CT and SPECT/CT. Semin Nucl Med (2009) 1.48
Multifunctional gold nanoparticles for diagnosis and therapy of disease. Mol Pharm (2013) 1.48
Nanoparticulate assemblies of amphiphiles and diagnostically active materials for multimodality imaging. Acc Chem Res (2009) 1.42
Inflammation imaging in atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 1.38
Monolayer coated gold nanoparticles for delivery applications. Adv Drug Deliv Rev (2011) 1.36
Templated spherical high density lipoprotein nanoparticles. J Am Chem Soc (2009) 1.34
High-density lipoprotein-based contrast agents for multimodal imaging of atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 1.30
Report of the National Heart, Lung, and Blood Institute working group on the translation of cardiovascular molecular imaging. Circulation (2011) 1.23
Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery. Nano Lett (2011) 1.21
RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe. FASEB J (2010) 1.21
The biological properties of iron oxide core high-density lipoprotein in experimental atherosclerosis. Biomaterials (2011) 1.21
Iron oxide core oil-in-water emulsions as a multifunctional nanoparticle platform for tumor targeting and imaging. Biomaterials (2009) 1.15
New Applications of Cardiac Computed Tomography: Dual-Energy, Spectral, and Molecular CT Imaging. JACC Cardiovasc Imaging (2015) 1.14
Modified natural nanoparticles as contrast agents for medical imaging. Adv Drug Deliv Rev (2009) 1.12
Nanoparticle contrast agents for computed tomography: a focus on micelles. Contrast Media Mol Imaging (2014) 1.11
Challenges associated with Penetration of Nanoparticles across Cell and Tissue Barriers: A Review of Current Status and Future Prospects. Nano Today (2014) 1.09
Effect of computed tomography scanning parameters on gold nanoparticle and iodine contrast. Invest Radiol (2012) 1.09
An approach to molecular imaging of atherosclerosis, thrombosis, and vascular inflammation using microparticles of iron oxide. Atherosclerosis (2009) 1.08
A fluorescent, paramagnetic and PEGylated gold/silica nanoparticle for MRI, CT and fluorescence imaging. Contrast Media Mol Imaging (2010) 1.07
Gold nanocrystal labeling allows low-density lipoprotein imaging from the subcellular to macroscopic level. ACS Nano (2013) 1.07
Comparison of synthetic high density lipoprotein (HDL) contrast agents for MR imaging of atherosclerosis. Bioconjug Chem (2009) 1.05
Annexin A5-functionalized bimodal nanoparticles for MRI and fluorescence imaging of atherosclerotic plaques. Bioconjug Chem (2010) 1.04
Multifunctional Magnetic Nanoparticles for Medical Imaging Applications. J Mater Chem (2009) 1.03
Tailoring of biomimetic high-density lipoprotein nanostructures changes cholesterol binding and efflux. ACS Nano (2011) 1.00
Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation. Sci Adv (2015) 0.99
Quantum dot and Cy5.5 labeled nanoparticles to investigate lipoprotein biointeractions via Förster resonance energy transfer. Nano Lett (2010) 0.98
Macrophage-specific RNA interference targeting via "click", mannosylated polymeric micelles. Mol Pharm (2013) 0.98
Surface functionalization of gold nanoparticles with red blood cell membranes. Adv Mater (2013) 0.97
Nanobiotechnology applications of reconstituted high density lipoprotein. J Nanobiotechnology (2010) 0.97
Single step reconstitution of multifunctional high-density lipoprotein-derived nanomaterials using microfluidics. ACS Nano (2013) 0.96
Inorganic-organic hybrid nanomaterials for therapeutic and diagnostic imaging applications. Int J Mol Sci (2011) 0.93
HDL as a contrast agent for medical imaging. Clin Lipidol (2009) 0.92
Recent Advances in Higher-Order, Multimodal, Biomedical Imaging Agents. Small (2015) 0.91
Multifunctional imaging nanoprobes. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 0.91
High-relaxivity gadolinium-modified high-density lipoproteins as magnetic resonance imaging contrast agents. J Phys Chem B (2009) 0.91
Molecular imaging in cardiovascular disease: targets and opportunities. Nat Rev Cardiol (2009) 0.91
Collagen-specific peptide conjugated HDL nanoparticles as MRI contrast agent to evaluate compositional changes in atherosclerotic plaque regression. JACC Cardiovasc Imaging (2013) 0.90
Atherosclerotic plaque targeting mechanism of long-circulating nanoparticles established by multimodal imaging. ACS Nano (2015) 0.90
C-reactive protein induced rearrangement of phosphatidylcholine on nanoparticle mimics of lipoprotein particles. J Phys Chem B (2010) 0.89
Nanoparticles for concurrent multimodality imaging and therapy: the dawn of new theragnostic synergies. Eur J Nucl Med Mol Imaging (2009) 0.89
Monocytes and macrophages as nanomedicinal targets for improved diagnosis and treatment of disease. Expert Rev Mol Diagn (2013) 0.88
Imaging apolipoprotein AI in vivo. NMR Biomed (2011) 0.88
A versatile and tunable coating strategy allows control of nanocrystal delivery to cell types in the liver. Bioconjug Chem (2011) 0.88
Molecular imaging of cell-based cancer immunotherapy. Mol Biosyst (2011) 0.88
High-Density Lipoproteins: Nature's Multifunctional Nanoparticles. ACS Nano (2016) 0.87
Nanotechnology for synthetic high-density lipoproteins. Trends Mol Med (2010) 0.86
Nanoparticles as magnetic resonance imaging contrast agents for vascular and cardiac diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 0.86
Emerging applications of nanotechnology for the diagnosis and management of vulnerable atherosclerotic plaques. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 0.84
HDL-mimetic PLGA nanoparticle to target atherosclerosis plaque macrophages. Bioconjug Chem (2015) 0.83
Inorganic nanocrystals as contrast agents in MRI: synthesis, coating and introduction of multifunctionality. NMR Biomed (2013) 0.83
Systematic in vitro toxicological screening of gold nanoparticles designed for nanomedicine applications. Toxicol In Vitro (2015) 0.82
Dextran coated bismuth-iron oxide nanohybrid contrast agents for computed tomography and magnetic resonance imaging. J Mater Chem B Mater Biol Med (2014) 0.81
Dendrimer-entrapped gold nanoparticles as potential CT contrast agents for blood pool imaging. Nanoscale Res Lett (2012) 0.81
Quantitative molecular profiling of biomarkers for pancreatic cancer with functionalized quantum dots. Nanomedicine (2012) 0.81
Nanomedical Theranostics in Cardiovascular Disease. Curr Cardiovasc Imaging Rep (2011) 0.81
Lipoproteins and lipoprotein mimetics for imaging and drug delivery. Adv Drug Deliv Rev (2016) 0.81
Nanoparticles for Cardiovascular Imaging and Therapeutic Delivery, Part 1: Compositions and Features. J Nucl Med (2015) 0.80
Insights into atherosclerosis using nanotechnology. Curr Atheroscler Rep (2010) 0.80
Strategies for Target-Specific Contrast Agents for Magnetic Resonance Imaging. Curr Mol Imaging (2012) 0.80
Synthesis, X-ray Opacity, and Biological Compatibility of Ultra-High Payload Elemental Bismuth Nanoparticle X-ray Contrast Agents. Chem Mater (2014) 0.80
Membrane mimetic surface functionalization of nanoparticles: methods and applications. Adv Colloid Interface Sci (2013) 0.79
Quantitative characterization of the lipid encapsulation of quantum dots for biomedical applications. Nanomedicine (2011) 0.79
Optimization of K-edge imaging for vulnerable plaques using gold nanoparticles and energy resolved photon counting detectors: a simulation study. Phys Med Biol (2013) 0.79
Micelle-Encapsulated Quantum Dot-Porphyrin Assemblies as in Vivo Two-Photon Oxygen Sensors. J Am Chem Soc (2015) 0.79
Labeling monocytes with gold nanoparticles to track their recruitment in atherosclerosis with computed tomography. Biomaterials (2016) 0.79
Recombinant high-density lipoprotein nanoparticles containing gadolinium-labeled cholesterol for morphologic and functional magnetic resonance imaging of the liver. Int J Nanomedicine (2012) 0.78
Nanoclusters of iron oxide: effect of core composition on structure, biocompatibility, and cell labeling efficacy. Bioconjug Chem (2012) 0.78
Lipid-Mediated Targeting with Membrane-Wrapped Nanoparticles in the Presence of Corona Formation. ACS Nano (2016) 0.78
Multimodal iron oxide nanoparticles for hybrid biomedical imaging. NMR Biomed (2012) 0.78
High spectral and spatial resolution X-ray transmission radiography and tomography using a Color X-ray Camera. Nucl Instrum Methods Phys Res A (2014) 0.78
Nanotechnology in interventional cardiology. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 0.78
In vitro uptake of apoptotic body mimicking phosphatidylserine-quantum dot micelles by monocytic cell line. Nanoscale Res Lett (2014) 0.78
Nanomedicines for Endothelial Disorders. Nano Today (2015) 0.77
Nanocrystal Core Lipoprotein Biomimetics for Imaging of Lipoproteins and Associated Diseases. Curr Cardiovasc Imaging Rep (2013) 0.77
Lipoprotein-Related and Apolipoprotein-Mediated Delivery Systems for Drug Targeting and Imaging. Curr Med Chem (2015) 0.75
Improved sensitivity of computed tomography towards iodine and gold nanoparticle contrast agents via iterative reconstruction methods. Sci Rep (2016) 0.75
Gold silver alloy nanoparticles (GSAN): an imaging probe for breast cancer screening with dual-energy mammography or computed tomography. Nanoscale (2016) 0.75
Tunable, biodegradable gold nanoparticles as contrast agents for computed tomography and photoacoustic imaging. Biomaterials (2016) 0.75
Conformational Changes in High-Density Lipoprotein Nanoparticles Induced by High Payloads of Paramagnetic Lipids. ACS Omega (2016) 0.75
Vascular targeting of nanoparticles for molecular imaging of diseased endothelium. Adv Drug Deliv Rev (2016) 0.75
Superparamagnetic Nanoparticles for Atherosclerosis Imaging. Nanomaterials (Basel) (2014) 0.75
Multi-Material Decomposition using Low-Current X-Ray and a Photon-Counting CZT Detector. IEEE Nucl Sci Symp Conf Rec (1997) (2011) 0.75
Use of Nanoparticle Contrast Agents for Cell Tracking with Computed Tomography. Bioconjug Chem (2017) 0.75
Tunable and noncytotoxic PET/SPECT-MRI multimodality imaging probes using colloidally stable ligand-free superparamagnetic iron oxide nanoparticles. Int J Nanomedicine (2017) 0.75
The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest (1955) 31.08
Quantum dots for live cells, in vivo imaging, and diagnostics. Science (2005) 21.62
Atherosclerosis. Nature (2000) 15.95
Quantum dot bioconjugates for imaging, labelling and sensing. Nat Mater (2005) 12.97
Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials (2005) 11.01
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb (1994) 8.54
Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science (1996) 8.29
Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed (2004) 6.94
Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol (2005) 5.80
Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci U S A (1992) 5.75
Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett (1990) 5.14
Surface plasmon resonance scattering and absorption of anti-EGFR antibody conjugated gold nanoparticles in cancer diagnostics: applications in oral cancer. Nano Lett (2005) 4.70
Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta (1991) 4.16
Imaging of atherosclerotic cardiovascular disease. Nature (2008) 4.14
Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med (1998) 3.85
Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation (2006) 3.57
Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med (2007) 3.40
HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov (2005) 3.00
Antibiofouling polymer-coated gold nanoparticles as a contrast agent for in vivo X-ray computed tomography imaging. J Am Chem Soc (2007) 2.78
Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res (2003) 2.70
Simultaneous multicolor imaging of five different lymphatic basins using quantum dots. Nano Lett (2007) 2.46
Reconstitution of high-density lipoproteins. Methods Enzymol (1986) 2.37
Molecular imaging of cardiovascular disease. Circulation (2007) 2.33
MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov (2006) 2.30
MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J (2005) 2.03
Quantum dots with a paramagnetic coating as a bimodal molecular imaging probe. Nano Lett (2006) 1.98
In vivo magnetic resonance imaging of acute brain inflammation using microparticles of iron oxide. Nat Med (2007) 1.90
Multimodal MRI contrast agents. J Biol Inorg Chem (2007) 1.86
Nondenaturing polyacrylamide gradient gel electrophoresis. Methods Enzymol (1986) 1.59
ABCA1-induced cell surface binding sites for ApoA-I. Arterioscler Thromb Vasc Biol (2007) 1.52
Virus-based nanoparticles (VNPs): platform technologies for diagnostic imaging. Adv Drug Deliv Rev (2006) 1.50
A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. Bioconjug Chem (2004) 1.47
Molecular magnetic resonance imaging with targeted contrast agents. J Cell Biochem (2003) 1.44
Properties of a versatile nanoparticle platform contrast agent to image and characterize atherosclerotic plaques by magnetic resonance imaging. Nano Lett (2006) 1.42
Applications of nanotechnology to atherosclerosis, thrombosis, and vascular biology. Arterioscler Thromb Vasc Biol (2005) 1.42
Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc Natl Acad Sci U S A (2005) 1.41
An ApoA-I mimetic peptide high-density-lipoprotein-based MRI contrast agent for atherosclerotic plaque composition detection. Small (2008) 1.34
Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat Clin Pract Cardiovasc Med (2006) 1.33
Lanthanides in magnetic resonance imaging. Chem Soc Rev (2006) 1.33
Chronic ethanol increases lipopolysaccharide-stimulated Egr-1 expression in RAW 264.7 macrophages: contribution to enhanced tumor necrosis factor alpha production. J Biol Chem (2002) 1.31
Self-assembled virus-like particles with magnetic cores. Nano Lett (2007) 1.28
Targeted imaging of human endothelial-specific marker in a model of adoptive cell transfer. Lab Invest (2006) 1.08
Delivery of diagnostic agents in computed tomography. Adv Drug Deliv Rev (1999) 1.05
Organic and inorganic nanoparticle hybrids. Langmuir (2005) 1.03
Multimodality nanotracers for cardiovascular applications. Nat Clin Pract Cardiovasc Med (2008) 1.01
Integrated magnetic bionanocomposites through nanoparticle-mediated assembly of ferritin. J Am Chem Soc (2007) 0.94
The role of macrophages in tumor development. Cell Oncol (2005) 0.91
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2010) 7.54
MiR-33 contributes to the regulation of cholesterol homeostasis. Science (2010) 6.93
The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. Nat Cell Biol (2003) 6.34
Long-term air pollution exposure and acceleration of atherosclerosis and vascular inflammation in an animal model. JAMA (2005) 5.83
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2010) 4.56
Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature (2011) 4.34
Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest (2011) 4.21
Imaging of atherosclerotic cardiovascular disease. Nature (2008) 4.14
Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci U S A (2004) 3.85
Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol (2013) 3.85
Quantitative 3D video microscopy of HIV transfer across T cell virological synapses. Science (2009) 3.69
Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med (2007) 3.40
Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation (2012) 3.38
Accuracy of 64-slice computed tomography to classify and quantify plaque volumes in the proximal coronary system: a comparative study using intravascular ultrasound. J Am Coll Cardiol (2006) 3.36
miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl Acad Sci U S A (2011) 3.35
Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol (2005) 3.34
Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J Am Coll Cardiol (2013) 3.25
Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci U S A (2005) 3.15
Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol (2013) 3.07
Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci U S A (2006) 3.00
Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci U S A (2007) 2.99
The neuroimmune guidance cue netrin-1 promotes atherosclerosis by inhibiting the emigration of macrophages from plaques. Nat Immunol (2012) 2.69
Cotranslocational degradation protects the stressed endoplasmic reticulum from protein overload. Cell (2006) 2.54
Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med (2008) 2.52
Atherosclerotic plaque composition: analysis with multicolor CT and targeted gold nanoparticles. Radiology (2010) 2.43
Recipes for creating animal models of diabetic cardiovascular disease. Circ Res (2007) 2.34
(18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol (2007) 2.32
Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity (2004) 2.27
Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol (2005) 2.23
Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading. Proc Natl Acad Sci U S A (2003) 2.23
Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab (2013) 2.20
HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells. Proc Natl Acad Sci U S A (2011) 2.16
Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int (2002) 2.15
Laser capture microdissection analysis of gene expression in macrophages from atherosclerotic lesions of apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A (2002) 2.13
Gradient echo acquisition for superparamagnetic particles with positive contrast (GRASP): sequence characterization in membrane and glass superparamagnetic iron oxide phantoms at 1.5T and 3T. Magn Reson Med (2006) 2.09
Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J Am Coll Cardiol (2010) 2.07
Optimization of ex vivo CT- and MR- imaging of atherosclerotic vessel wall changes. Int J Cardiovasc Imaging (2004) 2.04
(124)I-huA33 antibody PET of colorectal cancer. J Nucl Med (2011) 2.01
Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation (2002) 2.00
Cytoarchitecture of the human cerebral cortex: MR microscopy of excised specimens at 9.4 Tesla. AJNR Am J Neuroradiol (2002) 1.98
Quantum dots with a paramagnetic coating as a bimodal molecular imaging probe. Nano Lett (2006) 1.98
Rapid regression of atherosclerosis: insights from the clinical and experimental literature. Nat Clin Pract Cardiovasc Med (2008) 1.98
Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest (2011) 1.97
MRI-based attenuation correction for hybrid PET/MRI systems: a 4-class tissue segmentation technique using a combined ultrashort-echo-time/Dixon MRI sequence. J Nucl Med (2012) 1.92
Atherosclerosis and matrix metalloproteinases: experimental molecular MR imaging in vivo. Radiology (2009) 1.89
Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J (2014) 1.88
Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes (2002) 1.87
Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nat Biotechnol (2003) 1.87
Detection of high-risk atherosclerotic plaque: report of the NHLBI Working Group on current status and future directions. JACC Cardiovasc Imaging (2012) 1.85
Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation (2009) 1.84
Multimodality cardiovascular molecular imaging, Part II. Circ Cardiovasc Imaging (2009) 1.82
MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor. Magn Reson Med (2006) 1.79
MRI and characterization of atherosclerotic plaque: emerging applications and molecular imaging. Arterioscler Thromb Vasc Biol (2002) 1.79
Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques. Circulation (2011) 1.79
Brief report: increased apoptosis in advanced atherosclerotic lesions of Apoe-/- mice lacking macrophage Bcl-2. Arterioscler Thromb Vasc Biol (2008) 1.79
MRI of carotid atherosclerosis: clinical implications and future directions. Nat Rev Cardiol (2010) 1.78
Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov (2011) 1.78
Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc (2004) 1.77
Detection of neovessels in atherosclerotic plaques of rabbits using dynamic contrast enhanced MRI and 18F-FDG PET. Arterioscler Thromb Vasc Biol (2008) 1.73
Impact of noninsulin-dependent type 2 diabetes on carotid wall 18F-fluorodeoxyglucose positron emission tomography uptake. J Am Coll Cardiol (2012) 1.72
Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. J Clin Invest (2012) 1.71
Molecular, cellular and functional imaging of atherothrombosis. Nat Rev Drug Discov (2004) 1.71
Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation (2008) 1.68
Eliminating atherogenesis in mice by switching off hepatic lipoprotein secretion. Circulation (2003) 1.68
Endogenous expression of Hras(G12V) induces developmental defects and neoplasms with copy number imbalances of the oncogene. Proc Natl Acad Sci U S A (2009) 1.67
Atherothrombosis and high-risk plaque: Part II: approaches by noninvasive computed tomographic/magnetic resonance imaging. J Am Coll Cardiol (2005) 1.67
LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression. J Clin Invest (2010) 1.67
Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J Clin Invest (2004) 1.67
Effects of native and myeloperoxidase-modified apolipoprotein a-I on reverse cholesterol transport and atherosclerosis in mice. Arterioscler Thromb Vasc Biol (2014) 1.66
Mouse model of heterotopic aortic arch transplantation. J Surg Res (2003) 1.66
Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging (2009) 1.66
The Japanese tsunami and resulting nuclear emergency at the Fukushima Daiichi power facility: technical, radiologic, and response perspectives. J Nucl Med (2011) 1.65
In vivo characterization of a new abdominal aortic aneurysm mouse model with conventional and molecular magnetic resonance imaging. J Am Coll Cardiol (2011) 1.65
Molecular imaging in atherosclerosis, thrombosis, and vascular inflammation. Arterioscler Thromb Vasc Biol (2009) 1.65
Neuroimmune guidance cue Semaphorin 3E is expressed in atherosclerotic plaques and regulates macrophage retention. Arterioscler Thromb Vasc Biol (2013) 1.64
Narrowed TCR repertoire and viral escape as a consequence of heterologous immunity. J Clin Invest (2006) 1.64
Control of biochemical reactions through supramolecular RING domain self-assembly. Proc Natl Acad Sci U S A (2002) 1.63
Acyl-coenzymeA (CoA):cholesterol acyltransferase inhibition in rat and human aortic smooth muscle cells is nontoxic and retards foam cell formation. Arterioscler Thromb Vasc Biol (2004) 1.62
Improved biocompatibility and pharmacokinetics of silica nanoparticles by means of a lipid coating: a multimodality investigation. Nano Lett (2008) 1.62